ASCO-President Lynn M. Schuchter, MD, and her team at the Abramson Cancer Center at Penn Medicine are turning to the Center for Personalized Diagnostics to render genomic profiles for melanoma to determine which targeted therapies will best treat individual patients with the cancer.
Related Links
Published
August 14, 2014
Created by
BROADCASTMED